Editor-in-chief

World Class Dyslexia, Literacy, and Neuroscience Experts Gather with Educators for Two-Day Professional Learning Event

Retrieved on: 
Friday, March 29, 2024
Brain, Editor-in-chief, Administrator, ALTA, CE, Science, Professor, Dysgraphia, Dyscalculia, School, La Trobe University, Research, Policy, Literacy, Blog, Neuroscience, Role, Student, Continuing education, Learning Ally, Stanford University, WPD, Parent, Tutoring

PRINCETON, N.J., March 29, 2024 /PRNewswire/ -- Learning Ally, a national nonprofit working with U.S. K12 schools to strengthen reading outcomes, has announced the dates of its ninth Spotlight on Dyslexia virtual conference as June 5th and 6th, 2024.

Key Points: 
  • Spotlight on Dyslexia has become one of the most significant professional learning events in the field of education.
  • "By the fourth grade, an estimated 65% of children read below proficiency, and one in five faces a learning difference like dyslexia," said Dr. Terrie Noland, Learning Ally's VP of Educator Initiatives.
  • "Administrators and educators who participate in this conference and engage in ongoing professional learning programs will acquire the essential knowledge they need to become literacy leaders.
  • Networking opportunities with fellow educators in an innovative virtual environment where we celebrate schools and districts making strides in literacy instruction.

Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.

Retrieved on: 
Tuesday, March 12, 2024
Sycamore, Editor-in-chief, Growth, PHD, Biotechnology, Drug discovery, Patient, Research, Environmental technology, Acquisition, Cancer, Mentorship, DSM-IV codes, University, GMP, Clinical trial, Infection, Medical school, Adjunct, PharmaMar, Biomedical sciences, Family, Marketing, FDA, Biochimica et Biophysica Acta, Pharmaceutical industry

MELBOURNE, Fla., March 12, 2024 /PRNewswire/ -- Branded Legacy (OTC.PK: BLEG), Inc., a trailblazing BioTech holdings company, proudly announces the strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union.

Key Points: 
  • The acquisition brings forth over $500,000 in high-quality, ready-to-sell inventory and aligns seamlessly with Branded Legacy's dedication to quality, authenticity, and a commitment to natural ingredients.
  • David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm about the acquisition, stating, "Branded Legacy is thrilled to embrace Sycamore BioPharma into our family of companies.
  • Tyler Stone, President of Sycamore Biopharma, Inc., is also enthusiastic about the acquisition stating, "Branded Legacy brings significant strengths in areas where Sycamore BioPharma was seeing significant challenges.
  • The collaboration between Branded Legacy and Sycamore BioPharma is poised to unlock synergies across various business facets.

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on: 
Monday, February 26, 2024
Sengupta, HSCS, Rutgers University, Division, AI, Intelligence, Cardiac imaging, Education, Teaching, Echocardiography, University School, Editor-in-chief, ECG, American Medical Association, Society, Heart failure, Lung, TEDMED, European Society of Cardiology, Journal, FACC, MBBS, Publication, Holography, Research, Medical device

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points: 
  • Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
  • In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
  • I look forward to helping HeartSciences further advance the field of AI in cardiology.”

Seafood Expo North America/Seafood Processing North America Announces Keynote Address and Conference Sessions Featuring Top Professionals

Retrieved on: 
Friday, March 1, 2024
Giant, USDOL, Artificial intelligence, CBP, FC Volna Pinsk, Costco, Growth, Return, Sphere of influence, Private sector, FMI, Public affairs, Procurement, SAGE, International economics, Ultimate, Social media, Gigi, Marine Stewardship Council, Wrestling Federation of India, Outlook, Consumer, Marketing, Supply chain, Convention center, Diversified Communications, International, Editor-in-chief, Salmon, ESG, Giant Eagle, Politics, Bumblebee, Government, Country, Populism, Whole Foods Market, Brown University, Gender equality, Restaurant, Science, Vital

PORTLAND, Maine, March 1, 2024 /PRNewswire-PRWeb/ -- Seafood Expo North America/Seafood Processing North America, produced by Diversified Communications, announces keynote speaker Mark Blyth – William R. Rhodes '57 Professor of International Economics, The Watson Institute for International and Public Affairs at Brown University – and over 30 conference sessions presented by top professionals from across the sector on important topics facing the seafood industry.

Key Points: 
  • PORTLAND, Maine, March 1, 2024 /PRNewswire-PRWeb/ -- Seafood Expo North America/Seafood Processing North America, produced by Diversified Communications, announces keynote speaker Mark Blyth – William R. Rhodes '57 Professor of International Economics, The Watson Institute for International and Public Affairs at Brown University – and over 30 conference sessions presented by top professionals from across the sector on important topics facing the seafood industry.
  • The keynote session will be held on Sunday, March 10th at 11:00am in room 153CB.
  • The conference program, taking place during the three-day expo, will highlight timely topics and bring together a range of professionals to share their unique perspectives and insights.
  • Another session will include professionals from the Seafood Nutrition Partnership, H-E-B and Riverence talking through what drives U.S. consumer behavior and demand for seafood.

The International Myeloma Foundation (IMF) Welcomes Dr. S. Vincent Rajkumar as Chairperson of the Board

Retrieved on: 
Friday, February 2, 2024
Multiple myeloma, Clinical professor, Mayo Clinic, Jan, Research, Thalidomide, MD, Patient, Bone marrow, International Myeloma Foundation, IMF, Disease, Quality of life, European Journal, Education, Editor-in-chief

STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.

Key Points: 
  • STUDIO CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation (IMF) formally welcomed world-renowned myeloma clinician and researcher S. Vincent Rajkumar, MD as the foundation’s new Chairperson of the Board on Friday, February 2.
  • He has published more than 480 peer-reviewed papers primarily in the field of multiple myeloma and related plasma cell disorders.
  • "I am very grateful that the IMF Board of Directors agreed to approve Dr. Rajkumar as the new IMF Chairperson of the Board when I decided not to seek re-election.
  • "We are thrilled to welcome Dr. S. Vincent Rajkumar as the new Board Chairperson of the International Myeloma Foundation.

Dr. Samuel Lin Continues Partnership With Haute Beauty Network

Retrieved on: 
Friday, February 2, 2024
Partnership, Northwestern University, Certification, AAPS, ABMS, Plastic surgery, Knowledge, Science, Bachelor, Feinberg School of Medicine, Rhinoplasty, Division, Medical specialty, Internet celebrity, Expert, Plastic and Reconstructive Surgery, Biomedicine, Mentorship, Literature, MD Anderson Cancer Center, Elective surgery, Honors colleges and programs, Medical education, Harvard University, Harvard Medical School, Physician, Northwestern Memorial Hospital, Breast surgery, Biomedical engineering, Cure, Pearl, Editorial, Associate, University, Student, Editor-in-chief, Dentistry

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts. Dr. Lin received his Bachelor's degree in Biomedical Engineering at Northwestern University and was enrolled in the Honors Program for Medical Education at Northwestern University, Feinberg School of Medicine, Chicago, Illinois. He then completed a five-year-residency in Otolaryngology-Head and Neck Surgery followed by a three-year-residency in Plastic and Reconstructive Surgery at Northwestern Memorial Hospital. This was followed by a one-year fellowship appointment in Microvascular Reconstructive Surgery at the world-renowned University of Texas M.D. Anderson Cancer Center in Houston, Texas. Throughout the course of his training, Dr. Lin gained state-of-the-art skills in a multitude of reconstructive and cosmetic procedures with his background in Head and Neck Surgery providing him with additional expertise in Plastic and Reconstructive Surgery. He has also been named a Top Influencer in #PlasticSurgery.

Key Points: 
  • Nose Expert from Boston, Dr. Samuel Lin, continues his partnership with Haute Beauty Network, now in his sixth year.
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Dr. Samuel Lin is a double board certified Plastic Surgeon and Associate Professor of Surgery at Harvard Medical School who practices in Boston, Massachusetts.
  • Dr. Lin is board certified by both the American Board of Plastic Surgery and the American Board of Otolaryngology-Head and Neck Surgery.
  • Dr. Lin, his team, and his collaborators regularly publish scientific papers in the literature to further knowledge about plastic surgery and other topics.

Nexcella Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, January 4, 2024
Survival, Skinner, Editor-in-chief, Boston Medical Center, Doctor of Philosophy, Research, Rutgers University, Standard of care, AL amyloidosis, International Society, Hematology, Boston University, Daratumumab, Internal medicine, Patient, Journal, BMC, Medical device

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Nexcella, Inc. (“Nexcella”, “Company”, “We” or “Us”), announced that effective today, Vaishali Sanchorawala, MD, has joined the Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

Retrieved on: 
Thursday, January 4, 2024
Survival, Skinner, Editor-in-chief, Boston Medical Center, Doctor of Philosophy, Research, Rutgers University, Standard of care, AL amyloidosis, International Society, Hematology, Boston University, Daratumumab, Internal medicine, Patient, Journal, BMC

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Advisory Board.
  • I am excited to join the Nexcella team’s efforts to advance NXC-201, a promising CAR-T in relapsed/refractory AL Amyloidosis," commented Dr. Sanchorawala.
  • "Dr. Sanchorawala joining our scientific advisory board further demonstrates our leadership in relapsed/refractory AL Amyloidosis, where NXC-201 is the only CAR-T in development.
  • Dr. Sanchorawala completed residency at Rutgers Health/New Jersey Medical School and her fellowship in hematology/oncology at Boston University Medical Center.

Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board

Retrieved on: 
Tuesday, December 5, 2023
Fibromatosis, Surgical oncology, Radiology, STS, AG, Treatment, ESSO, Drug development, Research, Editor-in-chief, Thermosome, CMO, Stromal cell, Bristol Myers Squibb, SSO, Therapy, ISG, BioNTech, Society, Sarcoma, Oncology, Hematology, Board certification, Senior, Pharmaceutical industry

Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.

Key Points: 
  • Dr. Frank Hermann, MD, is a proficient clinical oncology professional with extensive experience in medical affairs, clinical research, and development.
  • Prior to that, he was Senior Director Clinical Development Oncology at BioNTech SE and Chief Development Officer at 4SC AG.
  • Earlier in his career, Frank Hermann worked in medical affairs and clinical development at Bristol-Myers Squibb, most recently as Associate Medical Director Immuno-Oncology.
  • “We are very pleased that Frank is joining Thermosome as Chief Medical Officer,” said Dr. Pascal Schweizer, co-founder, and CEO/CFO of Thermosome.

Mattamy Homes once again joins ranks of Best Places to Work in Phoenix

Retrieved on: 
Monday, October 23, 2023
Mattamy Homes, Camelback Inn, Organization, Editor-in-chief, The Last Best Place, Culture, American City Business Journals

SCOTTSDALE, AZ, Oct. 23, 2023 /PRNewswire/ - Mattamy Homes has once again been named one of the Best Places to Work by the Phoenix Business Journal.

Key Points: 
  • SCOTTSDALE, AZ, Oct. 23, 2023 /PRNewswire/ - Mattamy Homes has once again been named one of the Best Places to Work by the Phoenix Business Journal.
  • This is the third consecutive year that Mattamy Homes has been recognized.
  • "Being named a Best Place to Work is particularly meaningful as it's a reflection of how our team members feel about working at Mattamy," said Don Barrineau, President of Mattamy's Phoenix Division.
  • Honorees, including Mattamy Homes, will be featured in the Phoenix Business Journal's weekly print and digital edition on Friday, Dec. 15.